ClinicalTrials.gg
Not yet recruitingNCT07940322MT VTUpdated Nov 16, 2026

Moses Technology vs Vapor Tunnel in Low Power Laser Lithotripsy

An interventional study of Laser Lithotripsy with Moses Technology and Laser Lithotripsy with Vapor Tunnel in Lithiasis, Urinary, Stone, Urinary and Lithotripsy, Laser, sponsored by National and Kapodistrian University of Athens. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionUrinary CalculiRegistry: UrolithiasisReclassifiedWhy we changed it
Registry
Urolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Calculi
Why
  1. The study's listed conditions name Urinary Calculi, a narrower term within Urolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National and Kapodistrian University of Athens · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to compare two different laser settings used to break up kidney and ureter stones during surgery. The study will include adults with kidney or ureter stones who are scheduled to undergo a procedure in which an endoscope is passed through the urinary tract and a laser is used to break the stones into smaller pieces.

The main question is whether one laser setting can break up stones using less energy than the other, while maintaining similar treatment effectiveness and safety.

A total of 110 participants will be randomly assigned to one of two groups:

  • One group will undergo stone treatment using Moses Technology.
  • The other group will undergo stone treatment using Vapor Tunnel.

Both methods use a laser to break stones into smaller pieces. The study will compare the amount of laser energy used in relation to the size of the stone. Researchers will also assess the duration of the procedure, how completely the stones are cleared, the movement of stones during surgery, and any complications.

The findings may help urologists understand which laser setting is more efficient and whether it offers advantages during the treatment of kidney and ureter stones.

02

Conditions studied

  • Lithiasis, Urinary
  • Stone, Urinary
  • Lithotripsy, Laser

Browse trials for

03

In context

Urinary Calculi Reclassified

95 studies on the registry are indexed under Urinary Calculi; 19 are open to participants now.

This study's planned enrollment of 110 is close to the median of 120 across 61 interventional studies indexed under Urinary Calculi.

Browse Urinary Calculi studies →

Lead sponsor

National and Kapodistrian University of Athens is the lead sponsor of 177 studies on the registry; 55 are open to participants now.

Compared within Urinary Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • kidney/ureter stone
  • maximum stone diameter 5-20 mm (CT)
  • any stone composition
  • recent CT (3 months prior to procedure)
  • indication/no for laser lithotripsy
  • negative urine culture/adequate antibiotic preparation

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • inability/unwillingness to provide
  • radiolucent stones
  • ipsilateral urinary tract anatomical abnormalities
  • previous non-endoscopic surgery on the urinary tract
  • active urinary tract infection
  • acute kidney injury
  • bleeding disorders
  • inability to discontinue antithrombotic medication when required for the procedure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Moses Technology

    Procedure: Laser Lithotripsy with Moses Technology

  • Active comparator
    Vapor Tunnel

    Procedure: Laser Lithotripsy with Vapor Tunnel

Interventions

  • ProcedureLaser Lithotripsy with Moses Technology

    Laser lithotripsy using Moses Technology pulse modulation by Lumenis Pulse 120H Ho:YAG laser system, that produces a two-part laser pulse. The first low-energy part produces a vapor cavity through which the second high-energy part is transmitted to the stone without energy loss, increasing laser efficacy.

    Also known as: Ho:YAG Laser Lithotripsy

  • ProcedureLaser Lithotripsy with Vapor Tunnel

    Laser lithotripsy using Vapor Tunnel pulse modulation by Quanta Cyber Ho Ho:YAG laser system, which creates one low-power long-length laser pulse that prevents stone retropulsion.

    Also known as: Ho:YAG Laser Lithotripsy

06

What researchers measure

Primary outcomes

  1. Laser efficacy

    Total energy delivered by the Ho:YAG laser during stone lithotripsy, divided by the preoperative stone volume measured on computed tomography (CT). The result will be expressed in joules per cubic millimeter (J/mm³).

    Time frame: During ureteroscopic procedure

Secondary outcomes

  1. Laser-on time

    The cumulative duration of laser activation during stone lithotripsy, measured in minutes and recorded by the laser system.

    Time frame: During ureteroscopic procedure

  2. Operative time

    The total duration of the ureteroscopic procedure, measured in minutes from the beginning to the completion of the surgical procedure.

    Time frame: During ureteroscopic procedure

  3. Total energy

    The cumulative energy delivered by the Ho:YAG laser during stone lithotripsy, measured in joules (J) and recorded by the laser system.

    Time frame: During ureteroscopic procedure

  4. Lithotripsy rate

    Lithotripsy rate calculated as the preoperative stone volume, measured on CT in cubic millimeters, divided by the total laser activation time in seconds. Results will be expressed in mm³/s.

    Time frame: During ureteroscopic procedure

  5. Stone-free rate

    The proportion of patients with no residual stone fragments larger than 3 mm on postoperative computed tomography (CT).

    Time frame: One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)

Other outcomes

  1. Intraoperative complications

    The proportion of patients experiencing one or more complications during the ureteroscopic procedure, including their type and nature.

    Time frame: During ureteroscopic procedure

  2. Postoperative complications

    The proportion of patients experiencing postoperative complications, including their type and severity, classified according to the Clavien-Dindo classification system.

    Time frame: Within 30 days after the ureteroscopic procedure

  3. Length of hospital stay

    The duration of hospitalization, calculated as the number of days from hospital admission to hospital discharge.

    Time frame: From hospital admission until discharge

  4. Stone retropulsion

    Surgeon-assessed stone retropulsion during laser lithotripsy, evaluated according to the distance of stone displacement, frequency of retropulsion events, and impact of retropulsion on the completion of stone fragmentation.

    Time frame: During ureteroscopic procedure

07

Study locations

1 site
  • 2nd Department of Urology, Sismanogleio General Hospital
    Marousi, Attica 15126, Greece
08

References and documents

Publications

  • Ventimiglia E, Traxer O. What Is Moses Effect: A Historical Perspective. J Endourol. 2019 May;33(5):353-357. doi: 10.1089/end.2019.0012. PubMed 30892062 ↗
  • Ulvik O, AEsoy MS, Juliebo-Jones P, Gjengsto P, Beisland C. Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022 Jul;82(1):73-79. doi: 10.1016/j.eururo.2022.02.027. Epub 2022 Mar 14. PubMed 35300888 ↗
  • Terry RS, Ho DS, Scialabba DM, Whelan PS, Qi R, Ketterman BT, Preminger GM, Zhong P, Lipkin ME. Comparison of Different Pulse Modulation Modes for Holmium:Yttrium-Aluminum-Garnet Laser Lithotripsy Ablation in a Benchtop Model. J Endourol. 2022 Jan;36(1):29-37. doi: 10.1089/end.2021.0113. Epub 2021 Oct 29. PubMed 34269626 ↗
  • Rico L, Contreras P, Blas L, Butori S, Martinez E, Proietti S, Giusti G, Ameri C. Dusting efficacy between the regular setting of holmium laser (Ho:YAG) versus Vapor Tunnel pulse modality for non-complex kidney stones. Lasers Med Sci. 2023 Jul 28;38(1):168. doi: 10.1007/s10103-023-03828-9. PubMed 37501040 ↗
  • Mullerad M, Aguinaga JRA, Aro T, Kastin A, Goldin O, Kravtsov A, Assadi A, Badaan S, Amiel GE. Initial Clinical Experience with a Modulated Holmium Laser Pulse-Moses Technology: Does It Enhance Laser Lithotripsy Efficacy? Rambam Maimonides Med J. 2017 Oct 16;8(4):e0038. doi: 10.5041/RMMJ.10315. PubMed 28914602 ↗
  • Kim K, Seo YS, Chung PS, Eom JB. Analysis of lithotripsy efficiency and stone retropulsion displacement according to pulse characteristics of Ho: YAG laser with Moses effect. Lasers Surg Med. 2024 Feb;56(2):197-205. doi: 10.1002/lsm.23743. Epub 2023 Nov 30. PubMed 38037268 ↗
  • Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F, Sierra A, Juliebo-Jones P, Kwok JL, Tsaturyan A, Contreras P, Fossati N, Gallina A, Xavier Keller E, Knoll T, Kartalas Goumas I, Somani BK, Traxer O, Salonia A, Ventimiglia E. Is Pulse Modulation the Future of Laser Technology in Endourology: Evidence from a Literature Review - Section of EAU Endourology. Eur Urol Focus. 2025 Mar;11(2):347-355. doi: 10.1016/j.euf.2024.10.009. Epub 2024 Nov 13. PubMed 39542788 ↗
  • Black KM, Aldoukhi AH, Teichman JMH, Majdalany SE, Hall TL, Roberts WW, Ghani KR. Pulse modulation with Moses technology improves popcorn laser lithotripsy. World J Urol. 2021 Jun;39(6):1699-1705. doi: 10.1007/s00345-020-03282-0. Epub 2020 Jun 6. PubMed 32506386 ↗
  • Aldoukhi AH, Roberts WW, Hall TL, Ghani KR. Watch Your Distance: The Role of Laser Fiber Working Distance on Fragmentation When Altering Pulse Width or Modulation. J Endourol. 2019 Feb;33(2):120-126. doi: 10.1089/end.2018.0572. PubMed 30585738 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 32 interventional studies with no phase under Urinary Calculi, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 79. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Oct 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940322
Collaborators
Sismanogleio General Hospital
Responsible party
Polyvios Arseniou (Principal Investigator, National and Kapodistrian University of Athens) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Polyvios Arseniou
Contact
parseniou136@gmail.com
00306987553988
Lazaros Tzelves
Contact
lazarostzelves@gmail.com
00306944104974

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion